1Norrby SR, Gildon KM. Safety profile of meropenem: a re-view of nearly 5000 patients treated with meropenem [J].Scand J Infect Dis, 1999, 31: 3-10.
2Niitsuma K, Saitoh M, Kojimabara M, et al. Antimierobial susceptibility of P seudomonas aeruginosa isolated in Fukushi-ma Prefeeture[J]. Jpn J Antibiot, 2001, 54: 79-87.
3Watanabe A , Tokue Y , Takahashi H , et al. Comparative in vitro activity of carbapenem antibiotics against respiratory pathogens isolated between 1999 and 2000 [J]. J InfectChemother, 2001, 7: 267-271.
4Cunha BA. Nosocomial pneumonia. Diagnostic and therapeu-tic consideration[J]. Med Clin North Am, 2001, 85: 79-114.
5Christian BB. Guideline for treatment of hospital-acquired pneumonia. Sem Respir Criti Care Med,2002,23:457-469.
6American Thoracic Society. Hospital-acquired pneumonia :diagnosis,assessment of severity, initial antimicrobial therapy, and preventive strategies ;a consensus statement. Am J Respir Crit Care Med, 1996,153:1711-1725.
7Hanes SD, Demirkan K, Tolley E, et al. Risk factors for late-onset nosocomial pneumonia caused by Stenotrophomonas maltophilia in critically ill trauma patients. Clin Infect Dis,2002,35:228-235.
8Matin HK. Appropriate empirical antibacterial therapy for nosocomial infections. Drugs,2003,63:2157-2168.
9Moine P,Timsit JF, De Lassence A, et al. Mortality associated with late-onset pneumonia in the intensive care unit: results of a multicenter cohort study. Intensive Care Med ,2002 ,28 : 154-163.
